North America Viral Vector And Plasmid DNA Manufacturing Market Size, Share, Industry, Forecast and outlook (2024-2031)

North America Viral Vector And Plasmid DNA Manufacturing Market is segmented By Type (Dog, Cat), By Ingredient (Prebiotics and Probiotics, Enzymes, Omega-3 and Omega-6 Fatty Acids, Vitamins and Minerals, Others), By Form (Dry Food, Wet Food, Freeze-Dried Food, Others), By Application (Joint Health, Weight Management, Skin and Coat, Dental Health, Digestive Health, Others (Immunity, Mental Acuity, Calming)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Report Overview

North America Viral Vector And Plasmid DNA Manufacturing Market size is expected to reach USD billion by 2029, with growth at a CAGR of 25% during the forecast period 2022-2029. Increase the number of approvals for novel gene therapies

The increasing number of approvals for novel gene therapies by regulatory authorities is also a major factor contributing to the market's growth. For instance, Kymriah was the first gene therapy product approved in Canada in September 2018 for treating cancer. Health Canada approved Novartis Kymriah for pediatric, young adult, and adult patients.

There is an increase in the contract manufacturing business launch for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis launched the contract manufacturing business for plasmid DNA production. The company would establish additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-volume production service. 

Market Dynamics

The rising number of gene therapy patients is expected to drive the market growth 

An increasing number of patients opting for gene therapy to treat diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS is one of the major factors driving the growth of the market over the forecast period. The demand for plasmid DNA is growing owing to the increase in gene therapy development. Plasmid DNA is a prerequisite for producing AAV (adeno-associated virus), lentivirus, and other viral vector platforms. Adeno-associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection help in improving the vision of individuals suffering from Liber's Congenital Amaurosis. Gene therapy with viral vectors provides a complete cure to patients affected with genetic disorders and other life-threatening disorders, rather than easing symptoms with other treatments. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the global viral vector manufacturing market.

Increasing collaboration among companies and organizations for the development of viral vectors 

There is an increase in collaborations among companies and several organizations, research institutes, and non-profit organizations to develop and produce viral vectors and plasmid DNA. For instance, in May 2020, Dyno Therapeutics, a United States-based biotechnology company applying artificial intelligence (AI) to gene therapy, collaborated with Novartis to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. The partnership will allow the parties to utilize Dyno's CapsidMap artificial intelligence platform along with Novartis's expertise in gene therapy development and global commercialization to deliver innovative gene therapies to patients with serious diseases of the eye. 

Growth in viral vector manufacturing amid COVID-19 Pandemic

There is an increasing number of clinical studies conducted on viral vector manufacturing, emphasizing the potential of gene therapy to address important medical needs. Major pharmaceutical companies such as AstraZeneca, and Janssen Pharmaceuticals have developed COVID-19 viral vector-based vaccines in December 2020 and February 2021, respectively. Apart from these companies, several viral vector-based vaccines are currently in the development phase. This has accelerated the demand for viral vectors, thereby increasing revenue for viral vector manufacturers.

DataM Analysis Report

The North American viral vector and plasmid DNA manufacturing market is expected to expand at a sluggish CAGR of XX% during the forecast period (2022-2029). Availability of the U.S. FDA (Food and Drug Administration) approved gene therapy products and a rich product pipeline are the factors expected to augment the viral vector manufacturing market in the region during the forecast period. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage.

The significant incentives on offer through the Orphan Drugs Act (United States) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially-profitable venture. Many companies have been expanding their facilities and investing a significant amount of capital in the region. For instance, in April 2020, Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility. The projected expansion was expected to double the company’s gene therapy manufacturing capacity.

Market Overview

• According to DataM Intelligence latest research report on the viral vector and plasmid DNA manufacturing market in North America for the historical period 2020 & 2021 and the forecast period 2022–2029.
• In terms of revenue, the viral vector and plasmid DNA manufacturing market in North America is estimated to surpass US$ 2475.3 Mn by 2028, expanding at a CAGR of 20.3% throughout the forecast period.

Key Drivers

The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There is growing usage of viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is a rise in the number of clinical studies for examining the efficacy and safety of viral vectors. In addition, increase in the launch of the contract manufacturing business for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis launched the contract manufacturing business for plasmid DNA production.

Growing demand for vaccines drives the vaccinology segment

Based on application, the vaccinology segment is estimated to grow at the highest CAGR of 21.5% during the forecast period (2022-2029). The cancer segment accounted for the largest market share of  62% of the North American viral vector and plasmid DNA manufacturing market in 2020. Viral vector-based vaccines differ from most conventional vaccines in that they don’t contain antigens but rather use the body’s cells to produce them. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells.

North America Viral Vector And Plasmid DNA Manufacturing Market Scope

For More Insights Request Free Sample

North America Viral Vector And Plasmid Dna Manufacturing Market Competition Landscape

• Detailed profiles of providers of  viral vector and plasmid DNA manufacturing have been provided in the report to evaluate their financials, key product offerings, recent developments, and strategies
• Some of the key players operating in the North America Viral Vector And Plasmid DNA Manufacturing market are Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Cobra Biologics, Thermo Fisher Scientific, Inc. and Spark Therapeutics.

Strategic Partnerships

• The North American viral vector and plasmid DNA manufacturing market is highly competitive with the presence of several major companies in this region adopting various strategies to expand their business. 
• The market players are adopting various key strategies such as collaborations, partnerships, acquisitions, and product launches to expand their presence. Some other key strategies in the Viral Vector And Plasmid DNA Manufacturing market in North America are highlighted below:
• In July 2021, the company Thermo Fisher Scientific Inc. announced the launch of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif which will full fill the growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.
• In February 2021, Wacker has acquired the United States-based Genopis Inc., a major manufacturer of plasmid DNA in the United States.
• In February 2021, SIRION Biotech GmbH has signed a license and collaboration agreement with Sanofi, to develop an improved tissue-selective adeno-associated virus (AAV).
• In the North America viral vector and plasmid DNA manufacturing market report, we have discussed individual strategies, followed by company profiles of manufacturers of viral vector products. The ‘Competition Landscape’ section has been included in the report to provide readers with a dashboard view and company market share analysis of key players operating in North America.